Leerink Partnrs Issues Pessimistic Outlook for TSBX Earnings

Turnstone Biologics Corp. (NASDAQ:TSBX) – Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Turnstone Biologics in a research report issued to clients and investors on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings per share of ($0.26) for the quarter, down from their previous forecast of ($0.20). The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.69) EPS and FY2026 earnings at ($0.51) EPS.

Separately, Piper Sandler cut Turnstone Biologics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $3.75 to $0.40 in a report on Wednesday, February 5th.

Turnstone Biologics Price Performance

Shares of NASDAQ:TSBX opened at $0.38 on Thursday. The company has a market capitalization of $8.77 million, a P/E ratio of -0.12 and a beta of 2.04. Turnstone Biologics has a 1-year low of $0.34 and a 1-year high of $3.88. The firm’s 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $0.47.

Turnstone Biologics (NASDAQ:TSBX) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.13.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Turnstone Biologics stock. Takeda Pharmaceutical Co. Ltd. acquired a new position in Turnstone Biologics Corp. (NASDAQ:TSBX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 895,824 shares of the company’s stock, valued at approximately $448,000. Turnstone Biologics makes up approximately 1.7% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 8th largest position. Takeda Pharmaceutical Co. Ltd. owned approximately 3.87% of Turnstone Biologics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 52.51% of the company’s stock.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.